Specific COX-2 inhibitors: from bench to bedside
Non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin have been used to treat various ailments for over 100 years. As a class, these drugs are anti-inflammatory, analgesic and anti-pyretic, and they are widely used to treat chronic inflammatory diseases such as arthritis. The commercially available NSAIDs are approximately equivalent in terms of anti-inflammatory efficacy. All of the NSAIDs, however, also cause adverse effects in a significant fraction of people who consume them, and these side-effects frequently limit therapy. The most common side-effects associated with NSAID therapy are gastrointestinal (GI), with haemorrhage and frank ulceration seen in some patients; these lesions apparently can lead to increased morbidity in long-term NSAID users1. Renal and CNS effects are also observed. Because of these problems, a major goal of the pharmaceutical industry is the development of drugs that possess anti-inflammatory activity but lack the toxic effects associated with current NSAIDs. To date, no NSAIDs with the desired therapeutic profile have been commercially developed.
KeywordsInducible Cyclooxygenase Current NSAID Sheep Vesicular Gland Seminal Vesicle Sheep
Unable to display preview. Download preview PDF.
- 4.Vane JR, Botting RM. Biological properties of cyclooxygenase products. In: Cunningham FM (ed.) Lipid Mediators. London: Academic Press Ltd, 1994; 61–97.Google Scholar
- 27.Gans KR, Galbraith W, Roman RJ et al. Anti-inflammatory and safety profile of DuP 697; a novel orally effective prostaglandin synthesis inhibitor. J Pharmacol Exp Ther. 1989; 254: 180–187.Google Scholar
- 30.Chan C, Boyce S, Brideau C et al. Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: A novel non-steroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach. J Pharm Exp Ther. 1995; 274: 1531–1537.Google Scholar